Project support is conducted with our strategic partner, Amplia PharmaTek Inc., which is located in our Montreal complex.

With state­of-the art facilities and instrumentation, we provide expertise in in vitro pharmacology, in vivo PK, and in vivo pharmacology.


  • Target validation: siRNA, antisense oligonucleotides, and reference inhibitors. Endpoints monitored by gene expression and phenotypic assays.
  • Bio-reagent generation: recombinant drug target expression in bacteria and insect cells; scale-up to support structural biology.
  • Assay development and compound screening: customized assays for protein-protein interactions and major target classes (i.e., enzyme targets, GPCRs, kinases, nuclear receptors, and ion channels); colorimetric, fluorescence, luminescence, and radiometric, gene expression by qRT-PCR, Quantigene, ELISA, and Western blotting.
  • Phenotypic cell-based assays and in vitro toxicity assays: proliferation, cytotoxicity, apoptosis, migration, differentiation, and cell morphology changes via imaging. Toxicity assessment in human primary cells.
  • Biomarker studies in cells and tissues: SNP analysis, DNA sequencing, qRT-PCR, immunochemistry, ELISA, and determination of analytes in body fluids.


  • PK and tissue-specific exposure: NHP, canine, mini-pig, guinea pig, rat, mouse, and rabbit; general and microsurgery techniques
  • ln vivo pharmacology: Oncology, inflammatory / autoimmune, metabolic, fibrotic diseases, and pain; state-of-the-art animal surgery room, whole animal imaging, and specialized necropsy room; BSL 1 and BSL2 studies; PD effect in vivo analyzed by gene expression, post-translational protein modifications, cytokine/biomarker in body fluids, or lipid profiling in tissues.
  • General Mammalian Toxicology: mice, rats, and dogs under acute or chronic dosing, clinical observation, hematology, blood clinical chemistry, toxicokinetics, and histopathology.